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Background: BKPyV is associated with polyomavirus-associated nephropathy (PVAN), a major cause of graft
rejection in kidney transplant recipients (KTRs). Mutations occur in the transcriptional control region (TCR) of
BKPyV, but whether they are required for the development of PVAN is not completely understood. To this end,
we characterized BKPyV TCRs from KTRs to assess whether TCR mutations are associated with PVAN.
Study design: We analyzed urine and plasma samples of fifteen KTRs with biopsy-confirmed PVAN, presumptive
PVAN, or probable PVAN in order to explore the contents of the BKPyV virome. BKPyV TCRs were amplified and
deep sequenced to characterize the viral strains. Alterations in block structures and transcription factor binding
sites were investigated.
Results: The majority of sequences in both urine and plasma samples represented archetype BKPyV TCR. Minor
populations harboring rearranged TCRs were detected in all patient groups. In one biopsy-confirmed PVAN
patient rearranged TCRs predominated, and in another patient half of all reads represented rearranged se-
quences.
Conclusions: Although archetype BKPyV predominated in most patients, highest proportions and highest num-
bers of rearranged strains were detected in association with PVAN. TCR mutations seem not necessary for the
development of PVAN, but immunosuppression may allow increased viral replication giving rise to TCR variants
with enhanced replication efficiency.
1. Background
Polyomavirus-associated nephropathy (PVAN) is due to lytic infec-
tion of kidney tubular cells by reactivated BK polyomavirus (BKPyV).
Prolonged immunosuppression may result in reactivation of BKPyV and
replication in the kidneys leading to tissue damage characterized by
interstitial inflammation, tubular atrophy, and fibrosis [1–3]. PVAN is a
serious post-transplant complication of kidney transplantation:
4.2–8.0% of kidney transplant recipients (KTRs) develop PVAN which,
if left untreated, leads to graft rejection in approximately 15% of cases
[4–6]. In the lack of prophylactic or curative treatment for PVAN,
monitoring and early identification of patients at risk is the only option.
In order to prevent PVAN, monthly monitoring of BKPyV replication
in KTRs up to nine months post-transplant and thereafter every three
months at least until the second post-transplant year is recommended
[7]. Prolonged high-level BKPyV replication in blood (>1.0E+04
copies/mL) and urine (> 1.0E+07 copies/mL) always precedes PVAN
onset. Additionally, excretion of BKPyV-infected uroepithelial cells with
intranuclear inclusion bodies, i.e. decoy cells, in urine denotes BKPyV
reactivation in the kidneys [3,7]. A definitive diagnosis, however, re-
quires positive immunohistochemical staining for polyomavirus large T
antigen and the presence of typical cytopathic changes indicative of
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polyomavirus infection in kidney biopsy [7]. Approximately 30% of
KTRs experience BKPyV viruria and decoy cell shedding within a year
from transplantation; of those 7-17.3% will further develop BKPyV
DNAemia [5,8,9].
While the role of genomic rearrangements in the neurotropic JC
polyomavirus in progressive multifocal leukoencephalopathy are well
established [10,11], the role of BKPyV genome rearrangements in
PVAN is pending, despite intensive studies. Archetype BKPyV is as-
sumed to cause primary infection and establish persistence in the kid-
neys of up to 90% of individuals already in the childhood [12]. The
noncoding control region (NCCR) of archetype BKPyV, such as the WW
strain [13], regulates viral replication and gene expression. It can be
divided into arbitrary sequence blocks O (142 base pairs, bp), P (68 bp),
Q (39 bp), R (63 bp), and S (63 bp), respectively [14]. The NCCR
harbors a number of cellular transcription factor binding sites (TFBSs)
for Sp1, AP-1, NFAT, NF-1, and p53 [15–20]. The P, Q, R, and S blocks
constitute the transcriptional control region (TCR) [14] that is prone to
mutations such as rearrangements, deletions, and duplications. PVAN
patients frequently have mutations within the TCR that seem to in-
crease viral pathogenicity in vitro [21,22]. Also, mutations may en-
hance viral microRNA expression or modify the action of microRNAs on
viral gene expression [23].
In the present study we performed deep sequencing of BKPyV TCRs
present in paired plasma and urine samples of KTRs with or without
histological and clinical evidence of PVAN. The aim was to study
whether rearrangements within the TCR are associated with kidney
function and the development of PVAN.
2. Materials and methods
2.1. Kidney transplant recipients
Fifteen plasma and urine samples, both collected on the same day,
from 15 KTRs (5 females, 10 males; median age: 58 years, range:
23–72) were included in the study. The patients received a kidney
transplant between August 2009 and March 2014 at the Medical
University of Vienna, Austria. The patients were screened for BKPyV
replication according to current recommendations [7]. Detailed clinical
information is presented in Supplementary material.
2.2. Quantitative BKPyV and JCPyV real-time PCR
DNA was extracted from 200 μl plasma or urine using the automated
NucliSens EasyMag extractor (bioMérieux, Marcy l'Etoile, France) and
eluted into a final volume of 70 μl. BKPyV and JCPyV DNA were
quantified using real-time Taqman PCR with primers and probes lo-
cated within the minor capsid protein VP3. Amplification was per-
formed in two separate reactions using the same forward primer (5′-
TGC TCC TCA ATG GAT GTT GC-3′), the same fluorescence labelled
probe (5′-FAM-CGG GAC TGT AAC ACC TGC TCT TGA AGC-TAMRA-
3′), and either a BKPyV-specific reverse primer (5′-AGC TGC CCC TGG
ACA CTC-3′) or a JCPyV-specific reverse primer (5´-CAC GGG GTC CTT
CCT TTC-3´). PCR was run in a total volume of 25 μl containing 5 μl of
template DNA and TaqMan universal PCR master mix (PE Applied
Biosystems, Waltham, MA). Uniform PCR cycling conditions were:
3min at 50 °C, 10min at 95 °C followed by 45 cycles of 95 °C for 15 s,
55 °C and 72 °C each for 30 s. For quantification standard proficiency
panels distributed by the Quality Control for Molecular Diagnostics
(QCMD, Glasgow, UK) were used.
2.3. BKPyV TCR amplification
Total nucleic acids from plasma (180 μl) were extracted using the
Easymag Nuclisens instrument and nucleic acid isolation kit
(bioMérieux, Marcy l’Etoile, France). From six patients either 100 μl (5,
7, 9) or 80 μl (3, 4, 6) of original plasma was available. From urine
samples (140 μl) nucleic acids were isolated using the Qiagen viral RNA
mini kit (Qiagen, Hilden, Germany). Nucleic acids were eluted in 25 μl
(plasma) or 60 μl (urine) elution buffer. Amplification of the complete
TCR was performed as described previously [23].
2.4. Sequencing
Complete BKPyV TCRs (∼319 bp) were sequenced in single reads
using Illumina MiSeq sequencing (Illumina, San Diego, CA). For library
generation the amplicons were polished, A-tailed, adapter-ligated, and
purified. PCR amplification of the libraries was performed using
Phusion Hot Start II DNA Polymerase (Thermo Fisher Scientific), Index
P7 primers, and full-length P5 adapter primers. After pooling and size-
selection the library pool was subjected to paired-end sequencing on a
MiSeq Sequencer using the v3 600 cycle kit (Illumina).
2.5. Sequence analysis
The TCR sequence data were analyzed as described previously [23].
Only full-length TCR sequences containing both forward and reverse
primer sequences were clustered. The structure of each cluster was
confirmed by aligning cluster sequence with cluster reference sequence
using the Tablet tool [24] (Supplementary Figs. 1 and 2). Nucleotide
numbering is according to the TCR of BKPyV WW strain [13]
(AB211371.1; nucleotides 35…267), which was used as the archetype
BKPyV reference strain in sequence comparisons. Details of sequencing
analysis are given in Supplementary Material.
3. Results
3.1. Patient characteristics
In this study fifteen KTRs with BKPyV DNAemia and DNAuria
(>1.0E+ 03 DNA copies/mL) were included (Table 1). Two patients
(1, 2) had no clinical evidence of PVAN progression. Eight patients
(3–10) had high plasma BKPyV DNA loads (median: 2.50E+ 04,
range: 1.0E+ 04 – 3.80E+ 05) and were considered to have pre-
sumptive PVAN [7]. Five patients (11–15) had PVAN confirmed by
kidney histology performed within one week pre- or post-sampling
(proven PVAN [7];) and had high-level BKPyV DNAemia (median:
1.70E+ 06, range:1.40E+ 04 – 4.20E+ 08) accompanied by high
decoy cell shedding (median: 70%, range: 50-98%) and drop in kidney
function. Detailed clinical information is presented in Supplementary
material.
3.2. Archetype BKPyV predominated in all but two patients with biopsy-
confirmed PVAN
High amounts of original paired-end sequencing data were obtained
from all KTRs, and comparable amounts of post-analytic sequences
were gained from plasma and urine (Table 2). In plasma and urine of
KTRs with either presumptive or probable PVAN, the majority of se-
quences, on average 99.49%, represented archetype TCRs. Archetype
TCR was also frequent in plasma and urine of three (12–14) out of five
patients with histologically confirmed PVAN. In five presumptive PVAN
patients (3, 5, 6, 7, 9), and in one patient with proven PVAN (15) ex-
clusively archetype TCR sequences exceeded the cutoff of 1000 reads in
both plasma and urine.
The archetype BKPyV TCR sequences obtained from plasma and
urine of each individual patient were always identical and shared high
nucleotide identity (>97.01%) with archetype BKPyV WW reference
strain. A total of sixteen nucleotide point mutations (P block: A52 T,
A53 T, T65C, del88_89, A90C; R block: A145 G, A146 G, A147C,
C179 G, G181A, G182 T; S block: A222 G, T226 G, G228A, C239 G,
insT253_254) were identified in all patients with biopsy-confirmed
PVAN, in three patients with presumptive PVAN (3, 8, 9), and in two
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Table 2
Characterization of BK polyomavirus transcriptional control regions from urine and plasma of kidney transplant patients with proven PVAN, presumptive PVAN, or
probable PVAN. BKPyV WW strain (AB211371.1) was used as the archetype reference strain.
Patient Kidney status Source BKPyV load
(copies/mL)
Original read
amount
Post-analytic
read amount
Phenotype TCR
architecture
TCR
lenght
(bp)
Sequence identity
with archetype TCR
(%)
Proportion of all
sequences in the
sample (%)
1 Probable PVAN Urine 3.10E+07 194,648 125,244 Archetype P-Q-R-S 234 97.01 97.19
Rearranged P-(Q)-(R)-S 184 76.10 1.76
Plasma 5.40E+03 195,179 124,213 Archetype P-Q-R-S 234 97.01 98.17
Rearranged P-(Q)-(R)-S 207 85.90 1.93
2 Probable PVAN Urine 3.10E+08 173,797 121,460 Archetype P-Q-R-S 233 98.50 99.72
Plasma 2.00E+03 206,449 126,478 Archetype P-Q-R-S 233 98.50 96.01
Rearranged (P)-(Q)-R-S 188 79.40 3.98
3 Presumptive
PVAN
Urine 2.50E+08 179,658 129,518 Archetype P-Q-R-S 233 98.50 99.87
Plasma 2.70E+04 147,503 85,959 Archetype P-Q-R-S 233 98.50 99.97
4 Presumptive
PVAN
Urine 3.70E+07 197,551 134,458 Archetype P-Q-R-S 233 100 98.72
Rearranged P-(Q)-(S) 144 61.80 0.74
Plasma 1.00E+04 179,504 102,914 Archetype P-Q-R-S 233 100 98.90
Rearranged P-(Q)-(P)-Q-R-S 279 83.50 0.97
5 Presumptive
PVAN
Urine 1.00E+10 209,807 128,873 Archetype P-Q-R-S 233 100 98.10
Plasma 1.10E+04 197,996 137,845 Archetype P-Q-R-S 233 100 99.97
6 Presumptive
PVAN
Urine 1.00E+10 156,320 109,510 Archetype P-Q-R-S 233 100 98.76
Plasma 1.40E+05 174,402 111,574 Archetype P-Q-R-S 233 100 99.97
7 Presumptive
PVAN
Urine 1.10E+08 186,056 121,698 Archetype P-Q-R-S 233 100 99.26
Plasma 2.30E+04 210,522 139,579 Archetype P-Q-R-S 233 100 99.81
8 Presumptive
PVAN
Urine 2.80E+08 205,336 131,536 Archetype P-Q-R-S 234 97.01 92.37
Rearranged P-(Q)-(R)-S 185 76.10 3.88
Plasma 1.90E-04 170,259 107,301 Archetype P-Q-R-S 234 97.01 98.84
9 Presumptive
PVAN
Urine 5.10E+08 203,181 147,722 Archetype P-Q-R-S 233 98.13 98.31
Plasma 3.80E+05 201,098 142,933 Archetype P-Q-R-S 233 98.13 98.82
10 Presumptive
PVAN
Urine 1.00E+10 171,575 118,488 Archetype P-Q-R-S 233 98.50 96.10
Rearranged P-(Q)-(R)-S 184 77.70 0.89
Rearranged (P)-Q-R-S 215 91.0 0.51
Plasma 1.10E+05 197,232 135,637 Archetype P-Q-R-S 233 98.50 95.16
Rearranged P-(Q)-(R)-S 184 77.70 0.89
Rearranged P-(Q)-(R)-S 215 91.0 0.51
11 PVAN Urine 1.90E+11 289,372 217,378 Rearranged (P)-Q-R-S 216 90.67 27.6
Rearranged P-(P)-Q-R-S 266 84.30 18.17
Rearranged (P)-Q-R-S 226 91.60 15.18
Archetype P-Q-R-S 234 96.58 8.05
Rearranged P-(Q)-(R)-S 185 74.70 7.67
Rearranged P-(P)-Q-R-S 256 87.60 6.67
Rearranged P-(Q)-(P)-(Q)-
(R)-S
266 57.60 5.52
Rearranged P-(Q)-(P)-Q-R-S 256 86.90 2.30
Plasma 4.20E+08 322,959 231,178 Rearranged (P)-Q-R-S 216 90.67 46.93
Rearranged P-(P)-Q-R-S 266 84.30 7.19
Rearranged P-(Q)-(P)-(Q)-
(R)-S
266 57.60 7.14
Rearranged P-(Q)-(R)-S 208 84.40 5.19
Rearranged P-(Q)-(R)-(S)-
(Q)-(R)-S
232 65.20 2.88
Rearranged P-(Q)-(R)-(Q)-
(R)-S
225 59.30 2.60
Archetype P-Q-R-S 234 96.58 2.60
Rearranged P-(Q)-(P)-(Q)-S 198 48.80 2.38
Rearranged P-(Q)-(P)-Q-(R)-
(S)
249 63.60 2.01
Rearranged P-(Q)-(P)-Q-(R)-
(S)
187 49.60 1.82
Rearranged P-(Q)-(P)-(Q)-
(R)-S
248 61.40 1.56
Rearranged P-(Q)-(R)-(P)-
(Q)-(R)-S
230 68.0 1.51
Rearranged P-(Q)-(P)-Q-R-S 256 86.90 1.38
Rearranged P-(Q)-(P)-Q-(R)-
S
205 48.60 1.10
Rearranged P-(P)-Q-R-S 256 87.60 0.95
12 PVAN Urine 1.60E+11 293,225 233,812 Archetype P-Q-R-S 234 97.01 73.22
(continued on next page)
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probable PVAN patients (1, 2) (Supplementary Fig. 1). Some point
mutations were located in NF-1 TFBSs (T65C, C179 G, G181A, G182 T,
C239 G) and p53 (del88_89, A90C).
3.3. Rearranged BKPyV TCRs were found particularly in patients with
biopsy-confirmed PVAN
In contrast, rearrangements were common among confirmed PVAN
patients. The majority of sequences obtained from plasma and urine of
one KTR with histologically verified PVAN (patient 11) represented
Table 2 (continued)
Patient Kidney status Source BKPyV load
(copies/mL)
Original read
amount
Post-analytic
read amount
Phenotype TCR
architecture
TCR
lenght
(bp)
Sequence identity
with archetype TCR
(%)
Proportion of all
sequences in the
sample (%)
Rearranged P-(Q)-(R)-S 185 74.70 6.48
Rearranged P-(Q)-(R)-S 208 84.40 4.58
Rearranged P-(Q)-(R)-S 174 70.0 1.63
Rearranged P-(Q)-(S) 115 22.80 1.34
Rearranged P-(Q)-(R)-S 185 74.70 1.17
Rearranged P-(Q)-(R)-S 164 67.20 0.99
Rearranged P-(Q)-(R)-S 166 68.50 0.99
Rearranged P-(Q)-(S) 148 60.90 0.93
Plasma 1.10E+07 352,815 262,639 Archetype P-Q-R-S 234 97.01 57.11
Rearranged P-(Q)-(R)-S 185 74.70 4.75
Rearranged P-(Q)-(R)-S 208 84.40 4.38
Rearranged P-(Q)-(S) 148 60.90 2.47
Rearranged P-(Q)-(R)-S 166 68.50 2.32
Rearranged P-(Q)-(R)-S 185 74.70 1.90
Rearranged P-(Q)-(R)-S 174 70.0 1.33
Rearranged P-(Q)-(R)-S 180 73.0 1.14
Rearranged P-(Q)-(R)-S 171 69.90 0.82
Rearranged P-(Q)-S 167 68.90 0.76
Rearranged P-(Q)-(S) 163 67.20 0.65
13 PVAN Urine 2.90E+10 294,844 237,925 Archetype P-Q-R-S 233 98.50 98.77
Plasma 4.70E+05 360,608 263,356 Archetype P-Q-R-S 233 98.50 46.68
Rearranged P-(Q)-(S) 141 59.70 3.32
Rearranged P-(Q)-(S) 152 59.80 3.12
Rearranged P-(Q)-(R)-S 206 85.80 2.85
Rearranged P-Q-(R)-S 225 90.80 2.47
Rearranged P-(Q)-(S) 148 60.90 2.47
Rearranged P-Q-(R)-S 201 82.20 2.28
Rearranged P-Q-(R)-(S) 168 68.60 1.71
Rearranged P-(Q)-(S) 131 55.40 1.52
Rearranged P-Q-(R)-(S) 140 57.40 1.33
Rearranged P-(Q)-(S) 113 47.60 1.14
Rearranged P-(Q)-(R)-S 203 85.80 1.14
Rearranged P-Q-(R)-(S) 130 53.20 0.99
Rearranged P-(Q)-(R)-S 185 77.40 0.95
Rearranged P-(Q)-S 165 68.80 0.91
Rearranged P-(Q)-(R)-S 181 74.80 0.87
14 PVAN Urine 2.00E+11 308,733 251,022 Archetype P-Q-R-S 233 98.50 34.26
Rearranged (P)-Q-R-S 215 90.60 17.33
Rearranged P-(Q)-(R)-S 184 77.70 7.97
Rearranged P-(Q)-(S) 113 47.60 6.10
Rearranged P-(P)-(Q)-(S) 145 41.90 5.18
Rearranged P-(Q)-(R)-(P)-
(Q)-(R)-S
226 69.40 4.78
Rearranged P-(Q)-(R)-S 173 73.0 3.98
Rearranged P-(P)-Q-R-S 265 84.30 2.19
Rearranged P-(P)-Q-R-S 265 84.30 1.87
Rearranged P-(Q)-(R)-S 207 87.60 1.57
Rearranged (P)-Q-R-S 225 94.80 0.72
Rearranged P-(Q)-(R)-S 155 65.20 0.64
Rearranged P-(Q)-(R)-S 166 70.0 0.56
Rearranged P-(Q)-(R)-(S) 130 53.20 0.52
Plasma 1.70E+06 322,959 231,178 Archetype P-Q-R-S 233 98.50 46.27
Rearranged P-(Q)-(R)-S 184 77.70 12.86
Rearranged P-(Q)-(R)-(P)-
(Q)-(R)-S
226 69.40 10.81
Rearranged P-(Q)-(R)-S 173 73.0 5.41
Rearranged P-(P)-(Q)-(S) 145 41.90 5.19
Rearranged (P)-Q-R-S 215 90.60 4.28
Rearranged P-(Q)-(S) 113 47.60 2.60
Rearranged P-(Q)-(R)-S 206 87.10 3.94
Rearranged P-Q-(R)-(S) 130 53.20 1.30
15 PVAN Urine 6.30E+07 288,023 230,811 Archetype P-Q-R-S 234 97.01 99.71
Plasma 1.40E+04 281,712 217,932 Archetype P-Q-R-S 234 97.01 99.42
BKPyV, BK polyomavirus; TCR, transcriptional control region; PVAN, polyomavirus-associated nephropathy.
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rearranged sequences (84.64% of sequences in plasma, 83.11% in
urine). A considerable proportion of strains harbored an 18-bp deletion
in the P block (P32-49). Half of the sequences from both plasma
(46.39%) and urine (53.41%) of another PVAN patient (14) represented
rearranged TCR regions.
Small proportions of rearranged sequences were found in all PVAN
subgroups (Table 2, Supplementary Fig. 2). Rearranged TCRs were
found in both plasma and urine samples of one probable PVAN patient,
two patients with presumptive PVAN, and three patients with con-
firmed PVAN; in the plasma samples of one probable and one confirmed
PVAN patient; in the urine sample of one presumptive PVAN patient.
Rearranged strains were similarly frequent in plasma and urine. In
PVAN patients the average proportion of sequences representing rear-
ranged TCR was higher (urine: 45.03%, plasma: 33.57%) than in pre-
sumptive (2.01%, 1.19%) or probable (1.76%, 2.96%) PVAN patients.
The highest degree of variation in TCR architecture was observed in
association with biopsy-confirmed PVAN: while presumptive and
probable PVAN patients had at the most two TCR variants in both urine
and plasma, the number of different TCR variants ranged from 7 up to
15 in patients with proven PVAN (Table 2).
The most frequent individual TCR mutation in all three patient
groups was partial deletion of Q (Q13-39) and R blocks (R1-22)
(Table 2, Supplementary Fig. 2): in three proven PVAN patients, it was
present in on average 13.05% and 12.46% of all sequences in urine and
plasma, respectively. Another PVAN-associated TCR mutation was
partial deletion of Q and S blocks: it was found in urine and plasma
(average 3.72% and 2.86%, respectively) of two, and in plasma
(11.57%) of one patient with biopsy-confirmed PVAN, and also in the
urine of one presumptive PVAN patient. Duplications of both P (P47-
58) and R (R47-63) blocks were found in two proven PVAN patients.
Finally, urine and plasma samples (average: 16.62% and 4.28%, re-
spectively) of two proven PVAN patients and the urine of one patient
with presumptive PVAN (0.51%) harbored TCR sequences with either
8-bp (P42-49) or 18-bp deletion (P32-49) within the P block.
3.4. Mutations affected a number of TFBSs
More detailed analysis of rearranged BKPyV TCR regions revealed
changes in a number of TFBSs for AP-1, Sp1, NFAT, NF-1, and p53
(Supplementary Table). In all rearranged strains of patients with proven
PVAN and of two patients with presumptive PVAN, the number of
binding sites for NF-1 and Sp1 was decreased, mostly owing to deletions
affecting the archetypal Q and R blocks. The number of binding sites for
AP-1 was less affected in all patient groups. Both patients with probable
PVAN had viral strains with decreased number of binding sites for
transcriptional activators NFAT and NF-1.
4. Discussion
PVAN is characterized by enhanced replication of BKPyV in the
kidneys enabled by prolonged immunosuppression. Patient-specific
factors such as inflammation, genetic background, and cellular immune
response play essential roles in the outcome. Viral factors include re-
arrangements within the BKPyV TCR, which may increase pathogeni-
city by allowing enhanced replication and further emergence of muta-
tions, although their association with severe disease has remained
elusive [11,21,25–28]. To this end, we performed detailed character-
ization of BKPyV TCR populations in fifteen KTRs with either proven,
presumptive or probable PVAN.
In this small cohort we found that the majority of sequences re-
presented archetype TCR in all but two confirmed PVAN patients,
suggesting that TCR mutations may favor but are not be necessary for
the pathogenesis of PVAN. In archetype viral strains the individual
mutations frequently disrupted NF-1 and p53 TFBSs. All but two p53
(del88_89, A90C) and one NF-1 (C239 G) binding site mutations have
been previously detected in PVAN patients [18,22,23,26]. Single
nucleotide point mutations are commonly observed in association with
PVAN [23,26,29] but also in immunocompetent individuals [30]. Mu-
tations located in the binding sites for NF-1 or p53 might per se de-
crease BKPyV replication indirectly by inhibiting viral early gene ex-
pression [19] or by inhibiting the binding of large T antigen to the
NCCR [31]. In one PVAN patient an 18-bp deletion in the P block re-
sulting in loss of a NF-1 binding site was found, reported earlier in
kidney patients [26], and in all proven PVAN patients the binding sites
for NF-1 and Sp1 were affected, mostly due to Q or R deletion, which
was frequent in all patient groups. Similar modifications seem to occur
frequently in BKPyV strains associated with PVAN [20–22,26]. As many
of the individual mutations would not favor BKPyV replication, we
assume that the high replication activity is a result of the overall
composition of the viral strains, and possibly deletion of putative in-
hibitory sequences within the Q and R blocks, which was frequent
among our patients. High-level replication of archetype BKPyV has
been previously suggested to allow genetic alterations with further
enhanced viral replication efficiency and increased viral load
[11,21,25,32]. In the present work, the proportion and variety of re-
arranged strains increased along with viral loads towards confirmed
PVAN cases, and this could only be verified using highly sensitive se-
quencing techniques.
To our knowledge, this is the first detailed next-generation se-
quencing analysis of BKPyV TCR variation in paired plasma and urine
samples of KTRs with varying kidney status, albeit on a limited number
of patients. Samples with high BKPyV loads were selected for this study
to examine the multiplicity of strain variation and minute populations
among the individual BKPyV virome. We cannot completely rule out
the role of JC polyomavirus, observed in some patients, as JC poly-
omavirus can be a rare cause of PVAN [33,34]. Our results imply that
rearranged BKPyV is frequently found in PVAN, but agree with previous
studies proposing that rearranged BKPyV is not required for PVAN
[9,23,35]. The presence of rearranged viral strains in most patients
indicates, however, that enhanced viral replication after prolonged
immunosuppression may allow accumulation of mutations within the
TCR. Further studies on the emergence and accumulation of rearranged
strains are warranted to understand the pathogenesis of PVAN, and to
help earlier diagnosis and improve patient management.
Emergence of mutations within the body seems to apply to several
human polyomaviruses, as has been established for JCPyV (reviewed in
[36]) and recently described for Trichodysplasia spinulosa associated
polyomavirus TSPyV [37]. Whether these mutations are required for
pathogenesis (JCPyV and progressive multifocal leukoencephalopathy,
or PML), favor pathogenesis (BKPyV and PVAN), or are implicated in
pathogenesis (TSPyV and trichodysplasia spinulosa skin disease) re-
mains a topic for further studies.
In the present study we aimed to characterize the BKPyV popula-
tions in individual patients to elucidate the association between viral
strain variation and the pathogenesis of PVAN. High mutation rates in a
DNA virus are uncommon and the mechanisms are not well understood.
The majority of mutations are supposedly random, and many of them
would be disadvantageous, and the strains would thus not be detected
by sequencing. Viral strains with enhanced replication capacity causes
lytic infection and tissue damage, and they, albeit not required, are
associated with disease.
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